Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.

Bland KA, Kirkham AA, Bovard J, Shenkier T, Zucker D, McKenzie DC, Davis MK, Gelmon KA, Campbell KL.

Clin Breast Cancer. 2019 Jun 27. pii: S1526-8209(19)30253-8. doi: 10.1016/j.clbc.2019.05.013. [Epub ahead of print]

PMID:
31601479
2.

Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer.

Finn RS, Liu Y, Zhu Z, Martín M, Rugo HS, Diéras V, Im SA, Gelmon KA, Harbeck N, Lu DR, Gauthier E, Huang Bartlett C, Slamon DJ.

Clin Cancer Res. 2019 Sep 16. pii: clincanres.0751.2019. doi: 10.1158/1078-0432.CCR-19-0751. [Epub ahead of print]

PMID:
31527167
3.

"Chemotherapy-periodized" Exercise to Accommodate for Cyclical Variation in Fatigue.

Kirkham AA, Bland KA, Zucker DS, Bovard J, Shenkier T, McKenzie DC, Davis MK, Gelmon KA, Campbell KL.

Med Sci Sports Exerc. 2019 Sep 4. doi: 10.1249/MSS.0000000000002151. [Epub ahead of print]

PMID:
31490858
4.

Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ.

Breast J. 2019 Aug 25. doi: 10.1111/tbj.13516. [Epub ahead of print]

PMID:
31448513
5.

A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).

Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, Villa D, Cabanero M, Tu D, Tsao M, Seymour L.

Oncologist. 2019 Aug 16. pii: theoncologist.2019-0321. doi: 10.1634/theoncologist.2019-0321. [Epub ahead of print]

PMID:
31420468
6.

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.

Diéras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, Lu DR, Gauthier E, Schnell P, Mori A, Rugo HS, Finn RS.

Oncologist. 2019 Jun 19. pii: theoncologist.2019-0019. doi: 10.1634/theoncologist.2019-0019. [Epub ahead of print]

PMID:
31217344
7.

Maintenance of Fitness and Quality-of-Life Benefits From Supervised Exercise Offered as Supportive Care for Breast Cancer.

Kirkham AA, Bland KA, Wollmann H, Bonsignore A, McKenzie DC, Van Patten C, Gelmon KA, Campbell K.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):695-702. doi: 10.6004/jnccn.2018.7276.

PMID:
31200349
8.

Effects of exercise dose and type during breast cancer chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial.

An KY, Morielli AR, Kang DW, Friedenreich CM, McKenzie DC, Gelmon K, Mackey JR, Reid RD, Courneya KS.

Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32493. [Epub ahead of print]

PMID:
31173341
9.

Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients.

Zazuli Z, Otten LS, Drögemöller BI, Medeiros M, Monzon JG, Wright GEB, Kollmannsberger CK, Bedard PL, Chen Z, Gelmon KA, McGoldrick N, Kitchlu A, Vijverberg SJH, Masereeuw R, Ross CJD, Liu G, Carleton BC, Maitland-van der Zee AH.

Genes (Basel). 2019 May 10;10(5). pii: E364. doi: 10.3390/genes10050364.

10.

Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers.

Grewal JK, Tessier-Cloutier B, Jones M, Gakkhar S, Ma Y, Moore R, Mungall AJ, Zhao Y, Taylor MD, Gelmon K, Lim H, Renouf D, Laskin J, Marra M, Yip S, Jones SJM.

JAMA Netw Open. 2019 Apr 5;2(4):e192597. doi: 10.1001/jamanetworkopen.2019.2597.

11.

Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis.

Thibodeau ML, Zhao EY, Reisle C, Ch'ng C, Wong HL, Shen Y, Jones MR, Lim HJ, Young S, Cremin C, Pleasance E, Zhang W, Holt R, Eirew P, Karasinska J, Kalloger SE, Taylor G, Majounie E, Bonakdar M, Zong Z, Bleile D, Chiu R, Birol I, Gelmon K, Lohrisch C, Mungall KL, Mungall AJ, Moore R, Ma YP, Fok A, Yip S, Karsan A, Huntsman D, Schaeffer DF, Laskin J, Marra MA, Renouf DJ, Jones SJM, Schrader KA.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003681. doi: 10.1101/mcs.a003681. Print 2019 Apr.

12.

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ.

Breast Cancer Res Treat. 2019 Apr;174(3):719-729. doi: 10.1007/s10549-018-05125-4. Epub 2019 Jan 10.

13.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ.

J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19.

PMID:
30452337
14.

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.

Drögemöller BI, Wright GEB, Shih J, Monzon JG, Gelmon KA, Ross CJD, Amstutz U, Carleton BC; CPNDS Clinical Recommendations Group.

Breast Cancer Res Treat. 2019 Feb;173(3):521-532. doi: 10.1007/s10549-018-5027-0. Epub 2018 Nov 8.

PMID:
30411242
15.

A Longitudinal Study of the Association of Clinical Indices of Cardiovascular Autonomic Function with Breast Cancer Treatment and Exercise Training.

Kirkham AA, Lloyd MG, Claydon VE, Gelmon KA, McKenzie DC, Campbell KL.

Oncologist. 2019 Feb;24(2):273-284. doi: 10.1634/theoncologist.2018-0049. Epub 2018 Sep 26.

PMID:
30257888
16.

Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.

Le D, Gelmon KA.

Expert Rev Clin Pharmacol. 2018 Sep;11(9):833-839. doi: 10.1080/17512433.2018.1513321. Epub 2018 Aug 30. Review.

PMID:
30118334
17.

Corrigendum: Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.

Thibodeau ML, Reisle C, Zhao E, Martin LA, Alwelaie Y, Mungall KL, Ch'ng C, Thomas R, Ng T, Yip S, Lim H, Sun S, Young SS, Karsan A, Zhao Y, Mungall AJ, Moore RA, Renouf D, Gelmon K, Ma YP, Hayes M, Laskin J, Marra MA, Schrader KA, Jones SJM.

Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4). pii: a003327. doi: 10.1101/mcs.a003327. Print 2018 Aug. No abstract available.

18.

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP.

Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. No abstract available.

19.

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.

Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS.

J Natl Cancer Inst. 2019 Apr 1;111(4):419-430. doi: 10.1093/jnci/djy109.

20.

Can We Hang Our Hats on One Percent?

LeVasseur N, Gelmon KA.

Oncologist. 2018 Jun;23(6):642-644. doi: 10.1634/theoncologist.2018-0153. Epub 2018 May 4. No abstract available.

21.

Predictors of attendance to an oncologist-referred exercise program for women with breast cancer.

Bland KA, Neil-Sztramko SE, Kirkham AA, Bonsignore A, Van Patten CL, McKenzie DC, Gelmon KA, Campbell KL.

Support Care Cancer. 2018 Sep;26(9):3297-3306. doi: 10.1007/s00520-018-4180-7. Epub 2018 Apr 13.

PMID:
29651596
22.

A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours.

Aung KL, El-Khoueiry AB, Gelmon K, Tran B, Bajaj G, He B, Chen T, Zhu L, Poojary S, Basak S, Qi Z, Spreafico A, Fischer BS, Desai J.

Invest New Drugs. 2018 Dec;36(6):1026-1036. doi: 10.1007/s10637-018-0597-6. Epub 2018 Apr 10.

23.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, Ellis MJ, Pritchard KI, Clemons MJ, Badovinac-Crnjevic T, Han L, Gelmon KA, Rabaglio M, Elliott C, Shepherd LE, Goss PE.

J Natl Cancer Inst. 2018 Sep 1;110(9):1003-1008. doi: 10.1093/jnci/djy017.

24.

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.

Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CH, Iyer S, Johnston S, Ettl J, Harbeck N.

Ann Oncol. 2018 Apr 1;29(4):888-894. doi: 10.1093/annonc/mdy012.

25.

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.

Drögemöller BI, Brooks B, Critchley C, Monzon JG, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Hayden MR, Gelmon KA, Carleton BC, Ross CJD.

Clin Cancer Res. 2018 Apr 15;24(8):1866-1871. doi: 10.1158/1078-0432.CCR-17-2810. Epub 2018 Jan 22.

26.

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.

Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, Diéras V, Moulder S, Lipatov O, Colleoni M, Cristofanilli M, Lu DR, Mori A, Giorgetti C, Iyer S, Bartlett CH, Gelmon KA.

Ann Oncol. 2018 Mar 1;29(3):669-680. doi: 10.1093/annonc/mdx797.

27.

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.

Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.

Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.

28.

Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse.

Lohrisch C, Francl M, Sun S, Villa D, Gelmon KA.

Breast Cancer Res Treat. 2018 Feb;168(1):221-228. doi: 10.1007/s10549-017-4586-9. Epub 2017 Nov 27.

PMID:
29181718
29.

Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.

Laurberg T, Tramm T, Nielsen T, Alsner J, Nord S, Myhre S, Sørlie T, Leung S, Fan C, Perou C, Gelmon K, Overgaard J, Voduc D, Prat A, Cheang MCU.

Acta Oncol. 2018 Jan;57(1):38-43. doi: 10.1080/0284186X.2017.1401735. Epub 2017 Nov 25.

PMID:
29172851
30.

Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.

Niravath P, Chen B, Chapman JW, Agarwal SK, Welschhans RL, Bongartz T, Kalari KR, Shepherd LE, Bartlett J, Pritchard K, Gelmon K, Hilsenbeck SG, Rimawi MF, Osborne CK, Goss PE, Ingle JN.

Clin Breast Cancer. 2018 Feb;18(1):78-87. doi: 10.1016/j.clbc.2017.10.009. Epub 2017 Oct 16.

PMID:
29128193
31.

The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.

Kirkham AA, Eves ND, Shave RE, Bland KA, Bovard J, Gelmon KA, Virani SA, McKenzie DC, Stöhr EJ, Waburton DER, Campbell KL.

Breast Cancer Res Treat. 2018 Feb;167(3):719-729. doi: 10.1007/s10549-017-4554-4. Epub 2017 Nov 6.

PMID:
29110150
32.

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L.

Breast Cancer Res Treat. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.

PMID:
29027598
33.

Exercise Prescription and Adherence for Breast Cancer: One Size Does Not FITT All.

Kirkham AA, Bonsignore A, Bland KA, McKenzie DC, Gelmon KA, VAN Patten CL, Campbell KL.

Med Sci Sports Exerc. 2018 Feb;50(2):177-186. doi: 10.1249/MSS.0000000000001446.

PMID:
28991038
34.

Effectiveness of Oncologist-Referred Exercise and Healthy Eating Programming as a Part of Supportive Adjuvant Care for Early Breast Cancer.

Kirkham AA, Van Patten CL, Gelmon KA, McKenzie DC, Bonsignore A, Bland KA, Campbell KL.

Oncologist. 2018 Jan;23(1):105-115. doi: 10.1634/theoncologist.2017-0141. Epub 2017 Oct 5.

35.

Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.

Jones MR, Lim H, Shen Y, Pleasance E, Ch'ng C, Reisle C, Leelakumari S, Zhao C, Yip S, Ho J, Zhong E, Ng T, Ionescu D, Schaeffer DF, Mungall AJ, Mungall KL, Zhao Y, Moore RA, Ma Y, Chia S, Ho C, Renouf DJ, Gelmon K, Jones SJM, Marra MA, Laskin J.

Ann Oncol. 2017 Dec 1;28(12):3092-3097. doi: 10.1093/annonc/mdx523.

PMID:
28950338
36.

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).

Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, Meirow D, Pruneri G, Senkus E, Spanic T, Sutliff M, Travado L, Peccatori F, Cardoso F.

Breast. 2017 Oct;35:203-217. doi: 10.1016/j.breast.2017.07.017. Epub 2017 Aug 17.

37.

Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z, Parulekar WR, Shepherd L, Gelmon KA, Nielsen TO.

JAMA Oncol. 2017 Nov 9;3(11):e172085. doi: 10.1001/jamaoncol.2017.2085. Epub 2017 Nov 9.

38.

Protective effects of acute exercise prior to doxorubicin on cardiac function of breast cancer patients: A proof-of-concept RCT.

Kirkham AA, Shave RE, Bland KA, Bovard JM, Eves ND, Gelmon KA, McKenzie DC, Virani SA, Stöhr EJ, Warburton DER, Campbell KL.

Int J Cardiol. 2017 Oct 15;245:263-270. doi: 10.1016/j.ijcard.2017.07.037. Epub 2017 Jul 14.

PMID:
28735755
39.

Use of Neoadjuvant Platinum-The Ongoing Conundrum.

Rugo HS, Gelmon K.

JAMA Oncol. 2017 Oct 1;3(10):1312-1314. doi: 10.1001/jamaoncol.2017.1954. No abstract available.

PMID:
28715579
40.

Getting under the skin.

Lavoie JM, Gelmon KA.

Eur J Cancer. 2017 Sep;82:228-229. doi: 10.1016/j.ejca.2017.04.028. Epub 2017 Jun 4. No abstract available.

PMID:
28592381
41.

Optimal Management of Early and Advanced HER2 Breast Cancer.

Hurvitz SA, Gelmon KA, Tolaney SM.

Am Soc Clin Oncol Educ Book. 2017;37:76-92. doi: 10.14694/EDBK_175630. Review.

PMID:
28561711
42.

The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.

Weymann D, Laskin J, Roscoe R, Schrader KA, Chia S, Yip S, Cheung WY, Gelmon KA, Karsan A, Renouf DJ, Marra M, Regier DA.

Mol Genet Genomic Med. 2017 Mar 12;5(3):251-260. doi: 10.1002/mgg3.281. eCollection 2017 May.

43.

Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma.

Thibodeau ML, Reisle C, Zhao E, Martin LA, Alwelaie Y, Mungall KL, Ch'ng C, Thomas R, Ng T, Yip S, J Lim H, Sun S, Young SS, Karsan A, Zhao Y, Mungall AJ, Moore RA, J Renouf D, Gelmon K, Ma YP, Hayes M, Laskin J, Marra MA, Schrader KA, Jones SJM.

Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a001628. doi: 10.1101/mcs.a001628. Print 2017 Sep. Erratum in: Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4):.

44.

Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).

Ho D, Huang J, Chapman JW, Leitzel K, Ali SM, Shepherd L, Parulekar WR, Ellis CE, Crescnzo RJ, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Carney WP, Lipton A.

Breast Cancer Res Treat. 2017 Aug;164(3):571-580. doi: 10.1007/s10549-017-4273-x. Epub 2017 May 8.

PMID:
28484925
45.

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.

Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P.

Breast Cancer Res. 2017 May 2;19(1):54. doi: 10.1186/s13058-017-0836-3.

46.

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC.

JAMA Oncol. 2017 Nov 1;3(11):1558-1562. doi: 10.1001/jamaoncol.2017.0502.

47.

Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.

Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Bernstein V, Stambolic V, Chen BE, Goodwin PJ; From the CCTG, Alliance, SWOG, ECOG, NSABP Cooperative Groups.

Breast Cancer Res Treat. 2017 Jul;164(2):371-378. doi: 10.1007/s10549-017-4265-x. Epub 2017 Apr 26.

48.

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.

Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA.

Ann Oncol. 2017 Jul 1;28(7):1560-1568. doi: 10.1093/annonc/mdx152.

49.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Dec 1;28(12):3111. doi: 10.1093/annonc/mdx036. No abstract available.

50.

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. No abstract available. Erratum in: Ann Oncol. 2017 Dec 1;28(12 ):3111.

Supplemental Content

Loading ...
Support Center